Upload
others
View
10
Download
0
Embed Size (px)
Citation preview
Right and left ventricular arrhythmogenic
cardiomyopathy: two extremes of the clinical
expression of desmosomal disease
The Heart Hospital, UCLH Great Ormond Street Hospital
William J. McKenna, MD
Director, Institute of Cardiovascular Science
University College London
Exercise Test: 4.5min
11/2003 03/2005 05/2005 09/2005
ARVC Desmoplakin: normal echo/CMR
Arrhythmogenic Right Ventricular Cardiomyopathy
Autosomal Dominant ARVC Loci
ARVC1 14q23-24 Rampazzo, 1994
ARVC2 1q42-43 Rampazzo, 1995
ARVC3 14q12-22 Severini, 1996
ARVC4 2q32 Rampazzo, 1997
ARVC5 3p23 Ahmad, 1998
ARVC6 10q22.3 Melberg, 1999
ARVC7 10p12-14 Li, 2000
Naxos Disease - Hair
Naxos disease - keratoderma
Mutation in Plakoglobin cDNA(-catenin)
DESMOSOMEADHERENS JUNCTION
E-Cadherin Desmoglein-I
Plakoglobin-I
Desmoplakin
a-Catenin
b-Catenin
CytoSkeleton Cell-signalling
RV
LV
Carval-Huerta 1998, Norgett et al 2000
Recessive - 18 affected individuals (DCM)
Woolly hair, palmoplantar keratoderma
Carvajal SyndromeDesmoplakin mutation (7901/del G)
Mutation in Desmoplakin Domain
Binding to Plakoglobin Causes
Autosomal Dominant ARVC
Rampazzo et al 2002
Disease-Causing Mutations in
Desmosomal Proteins
Carvajal(Desmoplakin)
ARVC8 (Desmoplakin)
Plakophilin-2
Naxos(Plakoglobin)
• 82 ARVC pts
• 52% gene positive
• 14% >1 gene mutation
PKP2 = 80%
DSP = 2%
DSG2 = 16%
DSC2 = 0%
JUP = 2%
den Haan AD et al, Circ Cardiovasc Genet. 2009;2:428-435
Multiple gene mutations in ARVC
Seen in 7% probands
more severe form
early onset
more LV involvement
Bauce B et al. Heart Rhythm 2010;7:22–29
Multiple gene mutations in ARVC
PKP2 variant in 38 of 198 probands (19%)
A second variant was identified in 16 of the 38 (42%) and was associated with:
Early Onset
More severe form
Xu T et al. J Am Coll Cardiol 2010;55:587–97
49 probands SCD51 probands alive
Age at sudden cardiac death
100 Families with ARVC
Quarta, Circulation: in press
73%
27%
Gene mutation
No gene mutation
Genetics: living probands
Quarta, Circulation: in press
Desmosomal gene mutations in ARVC
27% 24%
36%13%
Desmoplakin
Plakophilin-2
Desmocollin-2
Desmoglein-2
Quarta, Circulation: in press
3%
41% 56% Gene mutation
No gene mutation
Not tested
85%
7%2% 2%4%
Single Mutation
Compound heterozygous
Double heterozygous
Three mutations in 3 genes
Four mutations in 2 genes
Genetics: families
Quarta, Circulation: in press
Disease penetrance in gene positive relatives
Definite 34%
Borderline 27%
No difference in frameshift (insertion or deletion) or a stop codon mutation vs missense or splice donor mutation (p=0.94)
Only 19% fulfilled 1994 ARVC criteria (p=0.03)
Quarta, Circulation: in press
Multiple desmosomal gene variants
More common in probands than in relatives 28.1% vs 9.7% (p=0.01)
In relatives, associated with 5 fold increase of risk of developing penetrant disease (OR=4.7, 95% CI 1.1-20.4, p=0.04)
Quarta, Circulation: in press
Arrhythmogenic
LV cardiomyopathy
Desmoplakin: LV ARVC
2034insA mutation Norman et al, 2005
Case III.7 – True FISP ciné
Four-chamber view
Case III.7 – Late enhancement
ID Age LVED
% pred
LVED
mm
LVES
mm
FS
%
Abn CMR
gad
ECG VT/ VES/
24hrs
II.6 67 142% 64 48 25 ICD in situ T II, III, VF, V4-6 RBBB VT*
III.7 62 109% 50 28 44 positive T II, III, VF, V4-6 RBBB VT*
III.10 47 120% 53 34 36 ND N 1316 R&L VES
III.17 41 98% 42 26 38 ND T II, III, VF 7 L VES#
III.20 46 128% 64 45 29 ND T II, III, VF, V3-6 815 L VES
IV.2 36 118% 51 35 31 ICD in situ R V1-2, T V3 LBBB VT*
IV.3 39 113% 50 33 34 ND N 3661 R&L VES
IV.5 31 105% 48 32 33 positive N 1795 L VES
IV.8 36 125% 54 38 29 ND T II, III, VF, V4-6 5938 L VES
IV.9 28 127% 58 43 26 positive T V4-6 5612 L VES
IV.14 22 117% 54 36 33 positive T II, III, VF 47 L VES
Arrhythmogenic Cardiomyopathy
Clinical
GeneticHistological
ARVC ALVC
Molecular Diagnostics in Clinic?Genetic Disease
Diagnosed
Mutation analysis
Mutation identified No mutation identified
Molecular testing of Ist degree
relatives
Negative Positive Clinical follow-up
Research Lab
Discharge (50%)
Recommendations
• Genetic testing should be considered for patients
who fulfil diagnostic criteria for ACM where
cascade screening may facilitate identification of
at risk relatives
• When a proven or probable disease causing
mutation is identified in a proband who fulfils
diagnostic criteria for ACM testing should be
considered in all first degree relatives (parents,
siblings, offspring)
• Mutation analysis should not be performed in
probands with isolated non diagnostic features of
ACM
Medical/Nursing
Professor William McKenna
Professor John Deanfield
Dr Perry Elliott
Dr Michael Burch
Dr Maite Tomé-Esteban
Dr Pier Lambiase
Dr Antonis Pantazis
Mr Simon Waller
Sr Linda Moss
Mr Michael Baldini
Sr Sarah Mead-Regan
Sr Jo Mander
Registrars / Fellows
Dr Caroline Coats
Dr Costas O’Mahony
Dr Christopher Critoph
Dr Vimal Patel
Dr Eleanor Wicks
Dr Juan Pablo Kaski
Dr Giovanni Quarta
Dr Margherita Calcagnino
Dr Shereen Al-Shaikh
Dr Samer Arnous
Arrhythmia/EP
Dr Edward Rowland
Dr Martin Lowe
Dr Tony Chow
Dr Oliver Segal
Dr Laurence Nunn
Dr James McCready
Dr Akbar Ahmed
Dr Syed Ahsan
Sr Eileen Firman
Imaging
Dr James Moon
Dr Denis Pellerin
Dr Camelia Demetrescu
Dr Mariana Mirabel
Kalaiarasi Janagarajan
Dr Srijita Sen-Chowdhry
Dr Dan Sado
Exercise Physiology
Bryan Mist, PhD
Beverley Bates
Dr Graham Derrick
Inherited Cardiovascular Disease Unit, UCL
Cardiomyopathy Association
Robert Hall
Peter McBride
Cardiac Risk in the Young (CRY)
Alison Cox
Steven Cox
Administration/Databasing
Peter Woods
Shaughan Dickie
Marietta Meyer
Harriet St Pierre
Sarah Wilson
Genetics
Mike Hubank, PhD
Petros Syrris, PhD
Sharon Jenkins
Demetra Georghiou
Angeliki Asimaki, PhD
Pathology
Dr Michael Ashworth
Dr Siân Hughes